Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non-Current Liabilities (2022 - 2025)

Atara Biotherapeutics' Other Non-Current Liabilities history spans 4 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 45.09% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.8 million, down 45.09%, while the annual FY2025 figure was $1.8 million, 45.09% down from the prior year.
  • Other Non-Current Liabilities reached $1.8 million in Q4 2025 per ATRA's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $35.1 million in Q4 2023 to a low of $616000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 4 years is $5.7 million, with a median of $4.3 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: surged 740.42% in 2023, then plummeted 90.68% in 2024.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $5.6 million in 2022, then surged by 530.41% to $35.1 million in 2023, then tumbled by 90.68% to $3.3 million in 2024, then plummeted by 45.09% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Other Non-Current Liabilities are $1.8 million (Q4 2025), $1.8 million (Q3 2025), and $1.7 million (Q2 2025).